Try a new search

Format these results:

Searched for:

person:charyd01 or goldfd01 or alin06 or bearal01 or benstj01 or caplin01 or chawlh01 or kaploe01 or kalacs01 or katzl01 or kaufmj10 or langsc01 or liud03 or lowenj01 or mattoa02 or mehtam02 or michaj02 or moderf01 or nazzal01 or scherj02 or skolne01 or soomri01 or tatapv01 or thompn01 or weissj02 or zhdano01 or cohene16 or meg271



Total Results:


Serum Metabolomic Markers of Protein-Rich Foods and Incident CKD: Results From the Atherosclerosis Risk in Communities Study

Bernard, Lauren; Chen, Jingsha; Kim, Hyunju; Wong, Kari E; Steffen, Lyn M; Yu, Bing; Boerwinkle, Eric; Levey, Andrew S; Grams, Morgan E; Rhee, Eugene P; Rebholz, Casey M
RATIONALE & OBJECTIVE/UNASSIGNED:While urine excretion of nitrogen estimates the total protein intake, biomarkers of specific dietary protein sources have been sparsely studied. Using untargeted metabolomics, this study aimed to identify serum metabolomic markers of 6 protein-rich foods and to examine whether dietary protein-related metabolites are associated with incident chronic kidney disease (CKD). STUDY DESIGN/UNASSIGNED:Prospective cohort study. SETTING & PARTICIPANTS/UNASSIGNED:A total of 3,726 participants from the Atherosclerosis Risk in Communities study without CKD at baseline. EXPOSURES/UNASSIGNED:Dietary intake of 6 protein-rich foods (fish, nuts, legumes, red and processed meat, eggs, and poultry), serum metabolites. OUTCOMES/UNASSIGNED:with ≥25% estimated glomerular filtration rate decline relative to visit 1, hospitalization or death related to CKD, or end-stage kidney disease). ANALYTICAL APPROACH/UNASSIGNED:Multivariable linear regression models estimated cross-sectional associations between protein-rich foods and serum metabolites. C statistics assessed the ability of the metabolites to improve the discrimination of highest versus lower 3 quartiles of intake of protein-rich foods beyond covariates (demographics, clinical factors, health behaviors, and the intake of nonprotein food groups). Cox regression models identified prospective associations between protein-related metabolites and incident CKD. RESULTS/UNASSIGNED:). LIMITATIONS/UNASSIGNED:Residual confounding and sample-storage duration. CONCLUSIONS/UNASSIGNED:We identified candidate biomarkers of fish, nuts, red and processed meat, eggs, and poultry. A fish-related metabolite, 1-docosahexaenoylglycerophosphocholine (22:6n3), was associated with a lower risk of CKD.
PMID: 38495599
ISSN: 2590-0595
CID: 5640042

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Vincenti, Flavio; Bestard, Oriol; Brar, Amarpali; Cruzado, Josep M; Seron, Daniel; Gaber, A Osama; Ali, Nicole; Tambur, Anat R; Lee, Helen; Abbadessa, Giovanni; Paul, Jo-Anne; Dudek, Markus; Siegel, Ruby J; Torija, Alba; Semiond, Dorothee; Lépine, Lucie; Ternes, Nils; Montgomery, Robert A; Stegall, Mark
BACKGROUND:Patients with calculated panel reactive antibody (cPRA) ≥80.00%, particularly those with cPRA ≥99.90%, are considered highly sensitized and underserved by the Kidney Allocation System. Desensitization removes circulating reactive antibodies and/or suppresses antibody production to increase chances of a negative crossmatch. CD38 is expressed highly on plasma cells, thus is a potential target for desensitization. METHODS:This was an open-label single-arm Phase 1/2 study investigating the safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. There were two cohorts, Cohorts A and B, which enrolled cPRA ≥99.90% and 80.00%-<99.90%, respectively. RESULTS:23 patients (12 Cohort A, 11 Cohort B) received isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks. Isatuximab was well tolerated with pharmacokinetic and pharmacodynamic profiles that indicated similar exposure to multiple myeloma trials. It resulted in decreases in CD38+ plasmablasts, plasma cells, and NK cells; and significant reductions in HLA-specific IgG-producing memory B cells. Overall response rate, based on a pre-defined composite desensitization end-point, was 83.3% and 81.8% in Cohorts A and B. Most responders had decreases in anti-HLA antibodies that were maintained for 26 weeks after the last dose. Overall cPRA values were minimally impacted, however, with only 9/23 patients (39%) having cPRA decreases to target levels. By study cut-off (median follow-up 68 weeks), 6 patients received transplant offers, of which 4 were accepted. CONCLUSIONS:In this open-label trial, isatuximab was well tolerated and resulted in a durable decrease in anti-HLA antibodies with partial desensitization activity.
PMID: 38147137
ISSN: 1533-3450
CID: 5623482

Association of Estimated Glomerular Filtration Rate and Albuminuria with Venous Thromboembolism

Zheng, Zhong; Pandit, Krutika; Chang, Alex R; Shin, Jung-Im; Charytan, David M; Grams, Morgan E; Surapaneni, Aditya
BACKGROUND:Chronic kidney disease (CKD) has been implicated as a risk factor for venous thromboembolism, but the evidence is limited to relatively healthy populations. The objective of the current study was to discern whether parameters of kidney function and damage are associated with the occurrence of venous thromboembolism after hospitalization. METHODS:We conducted a retrospective study including 23,899 and 11,552 adult individuals hospitalized within Geisinger Health System and NYU Langone Health from 2004 to 2019 and 2012 to 2022, respectively. A Poisson model was used to evaluate adjusted incidence rates of venous thromboembolism according to estimated glomerular filtration rate (eGFR) and albuminuria categories in each cohort. Cox proportional hazards models were used to analyze associations of eGFR and urinary albumin to creatinine ratio (UACR) with venous thromboembolism and hazard ratios were meta-analyzed across cohorts. RESULTS:Both lower eGFR and higher UACR were associated with higher risks of venous thromboembolism. In the Geisinger cohort, the incidence of venous thromboembolism after hospital discharge ranged from 10.7 (95% CI 9.2 - 12.6) events per 1000 person-years in individuals in G1A1 (eGFR >90 mL/min/1.73 m2 and UACR <30 mg/g) to 27.7 (95% CI 20.6 - 37.2) events per 1000 person-years in individuals with G4-5A3 (eGFR <30 mL/min/1.73 m2 and UACR >300 mg/g). A similar pattern was observed in the NYU cohort. Meta-analyses of the two cohorts showed that every 10 mL/min/1.73m2 reduction in eGFR below 60 mL/min/1.73m2 was associated with a 6% higher risk of venous thromboembolism (HR 1.06 [1.02 - 1.11], P = 0.01), and each two-fold higher UACR was associated with a 5% higher risk of venous thromboembolism (HR 1.05 [1.03 - 1.07], P <0.001). CONCLUSIONS:Both eGFR and UACR were independently associated with higher risk of venous thromboembolism after hospitalization. The incidence rate was higher with greater severity of CKD.
PMID: 37971889
ISSN: 1555-905x
CID: 5610872

Nephrologists should talk to their patients about climate change

Goldfarb, David S
PMID: 38240262
ISSN: 1473-6543
CID: 5624432

Let's stop talking about 'citrate toxicity'

Israni, Avantika; Goldfarb, David S
PURPOSE OF REVIEW/OBJECTIVE:Continuous renal replacement therapy (CRRT) is a vital medical intervention used in critically ill patients with acute kidney injury (AKI). One of the key components of adequate clearance with CRRT is the use of anticoagulants to prevent clotting of the extracorporeal circuit. Regional citrate anticoagulation is the most often recommended modality. The term 'citrate toxicity' is used to describe potential adverse effects of accumulation of citrate and subsequent hypocalcemia. However, citrate is itself not inherently toxic. The term and diagnosis of citrate toxicity are questioned in this review. RECENT FINDINGS/RESULTS:Citrate is being increasingly used for regional anticoagulation of the CRRT circuit. Citrate accumulation is infrequent and can cause hypocalcemia and metabolic alkalosis, which are potential adverse effects. Citrate itself, however, is not a toxic molecule. The term 'citrate toxicity' has been used to denote hypocalcemia and metabolic acidosis. However, citrate administration is well known to cause systemic and urinary alkalinization and under certain circumstances, metabolic alkalosis, but is not associated itself with any 'toxic' effects.We review the existing literature and debunk the perceived toxicity of citrate. We delve into the metabolism and clearance of citrate and question current data suggesting metabolic acidosis occurs as the result of citrate accumulation. SUMMARY/CONCLUSIONS:In conclusion, this article calls into question prevailing concerns about 'citrate toxicity'. We emphasize the need for a more nuanced understanding of its safety profile. We recommend discarding the term 'citrate toxicity' in favor of another frequently used, but more meaningful term: 'citrate accumulation'.
PMID: 37962170
ISSN: 1473-6543
CID: 5610622

Association of Low Glomerular Filtration Rate With Adverse Outcomes at Older Age in a Large Population With Routinely Measured Cystatin C

Fu, Edouard L; Carrero, Juan-Jesus; Sang, Yingying; Evans, Marie; Ishigami, Junichi; Inker, Lesley A; Grams, Morgan E; Levey, Andrew S; Coresh, Josef; Ballew, Shoshana H
BACKGROUND/UNASSIGNED:), which may be less accurate in older adults. OBJECTIVE/UNASSIGNED:) and 8 outcomes. DESIGN/UNASSIGNED:Population-based cohort study. SETTING/UNASSIGNED:Stockholm, Sweden, 2010 to 2019. PARTICIPANTS/UNASSIGNED:82 154 participants aged 65 years or older with outpatient creatinine and cystatin C testing. MEASUREMENTS/UNASSIGNED:Hazard ratios for all-cause mortality, cardiovascular mortality, and kidney failure with replacement therapy (KFRT); incidence rate ratios for recurrent hospitalizations, infection, myocardial infarction or stroke, heart failure, and acute kidney injury. RESULTS/UNASSIGNED:, and for KFRT they were 2.6 (CI, 1.2 to 5.8) and 1.4 (CI, 0.7 to 2.8), respectively. Similar findings were observed in subgroups, including those with a urinary albumin-creatinine ratio below 30 mg/g. LIMITATION/UNASSIGNED:No GFR measurements. CONCLUSION/UNASSIGNED:was more strongly associated with adverse outcomes and the associations were more uniform. PRIMARY FUNDING SOURCE/UNASSIGNED:Swedish Research Council, National Institutes of Health, and Dutch Kidney Foundation.
PMID: 38285982
ISSN: 1539-3704
CID: 5627392

Advance Care Planning and Palliative Care Consultation in Kidney Transplantation

Fisher, Marlena C; Chen, Xiaomeng; Crews, Deidra C; DeGroot, Lyndsay; Eneanya, Nwamaka D; Ghildayal, Nidhi; Gold, Marshall; Liu, Yi; Sanders, Justin J; Scherer, Jennifer S; Segev, Dorry L; McAdams-DeMarco, Mara A
RATIONALE & OBJECTIVE/OBJECTIVE:Because of the high risk of waitlist mortality and posttransplant complications, kidney transplant (KT) patients may benefit from advance care planning (ACP) and palliative care consultation (PCC). We quantified the prevalence and racial disparities in ACP and PCC among KT candidates and recipients. STUDY DESIGN/METHODS:Prospective cohort study. SETTING & PARTICIPANTS/METHODS:2,575 adult KT candidates and 1,233 adult recipients (2008-2020). EXPOSURE/METHODS:Race and ethnicity. OUTCOMES/RESULTS:All reports of ACP and PCC were abstracted from chart review. ACP was defined as patient self-report of an advance directive, presence of an advance directive in the medical record, or a documented goals-of-care conversation with a provider. PCC was defined as an ordered referral or a documented palliative care note in the medical record. ANALYTICAL APPROACH/METHODS:Racial/ethnic disparities in ACP/PCC were estimated using adjusted logistic regression. RESULTS:21.4% of KT candidates and 34.9% of recipients engaged in ACP. There were racial/ethnic disparities in ACP among KT candidates (White, 24.4%; Black, 19.1%; Hispanic, 15%; other race and ethnicity, 21.1%; P=0.008) and recipients (White, 39.5%; Black, 31.2%; Hispanic, 26.3%; other race and ethnicity, 26.6%; P=0.007). After adjustment, Black KT recipients had a 29% lower likelihood of engaging in ACP (OR, 0.71; 95% CI, 0.55-0.91) than White KT recipients. Among older (aged≥65 years) recipients, those who were Black had a lower likelihood of engaging in ACP, but there was no racial disparity among younger recipients (P=0.020 for interaction). 4.2% of KT candidates and 5.1% of KT recipients engaged in PCC; there were no racial disparities in PCC among KT candidates (White, 5.3%; Black, 3.6%; Hispanic, 2.5%; other race and ethnicity, 2.1%; P=0.13) or recipients (White, 5.5%; Black, 5.6%; Hispanic, 0.0%; other race and ethnicity, 1.3%; P = 0.21). LIMITATIONS/CONCLUSIONS:Generalizability may be limited to academic transplant centers. CONCLUSIONS:ACP is not common among KT patients, and minoritized transplant patients are least likely to engage in ACP; PCC is less common. Future efforts should aim to integrate ACP and PCC into the KT process. PLAIN-LANGUAGE SUMMARY/UNASSIGNED:Kidney transplant (KT) candidates and recipients are at elevated risk of morbidity and mortality. They may benefit from completing a document or conversation with their palliative care provider that outlines their future health care wishes, known as advance care planning (ACP), which is a component of palliative care consultation (PCC). We wanted to determine how many KT candidates and recipients have engaged in ACP or PCC and identify potential racial disparities. We found that 21.4% of candidates and 34.9% of recipients engaged in ACP. After adjustment, Black recipients had a 29% lower likelihood of engaging in ACP. We found that 4.2% of KT candidates and 5.1% of KT recipients engaged in PCC, with no racial disparities found in PCC.
PMID: 37734687
ISSN: 1523-6838
CID: 5620472

Organic Pollutant Exposure and CKD: A Chronic Renal Insufficiency Cohort Pilot Study

Charytan, David M; Wu, Wenbo; Liu, Mengling; Li, Zhong-Min; Kannan, Kurunthachalam; Trasande, Leonardo; Pal, Vineet Kumar; Lee, Sunmi; Trachtman, Howard; Appel, Lawrence J.; Chen, Jing; Cohen, Debbie L.; Feldman, Harold I.; Go, Alan S.; Lash, James P.; Nelson, Robert G.; Rahman, Mahboob; Rao, Panduranga S.; Shah, Vallabh O; Unruh, Mark L
ISSN: 2590-0595
CID: 5634782

Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations

Khan, Sadiya S; Matsushita, Kunihiro; Sang, Yingying; Ballew, Shoshana H; Grams, Morgan E; Surapaneni, Aditya; Blaha, Michael J; Carson, April P; Chang, Alexander R; Ciemins, Elizabeth; Go, Alan S; Gutierrez, Orlando M; Hwang, Shih-Jen; Jassal, Simerjot K; Kovesdy, Csaba P; Lloyd-Jones, Donald M; Shlipak, Michael G; Palaniappan, Latha P; Sperling, Laurence; Virani, Salim S; Tuttle, Katherine; Neeland, Ian J; Chow, Sheryl L; Rangaswami, Janani; Pencina, Michael J; Ndumele, Chiadi E; Coresh, Josef; ,
PMID: 37947085
ISSN: 1524-4539
CID: 5607782

Trial Emulation Methods

Shin, Jung-Im; Grams, Morgan E
PMID: 37783304
ISSN: 1523-6838
CID: 5614162